首页> 外文期刊>Bone marrow transplantation >Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia
【24h】

Recent decrease in non-relapse mortality due to GVHD and infection after allogeneic hematopoietic cell transplantation in non-remission acute leukemia

机译:非缓解性急性白血病因异基因造血细胞移植后由GVHD和感染引起的非复发死亡率的近期降低

获取原文
获取原文并翻译 | 示例
       

摘要

Although recent improvements have been indicated in the outcome after allogeneic hematopoietic cell transplantation (allo-HCT), little information is available on how changes in transplant modalities have affected the outcomes after allo-HCT in non-remission, based on patient age, donor source and disease type. We compared the incidence and causes of non-relapse mortality (NRM) after allo-HCT in non-remission among three consecutive four-year periods using a nationwide transplant outcome registry database. A total of 3308 patients with acute leukemia in non-remission were analyzed. The risk of NRM decreased over the three periods, and the hazard ratios (HRs) in 2001-2004 and 2005-2008 compared with 1997-2000 were 0.86 (95% CI, 0.70-1.06; P=0.16) and 0.65 (95% CI, 0.53-0.80; P<0.01), respectively. A significant decrease in the HR for overall mortality was also observed in 2005-2008 (HR 0.85; 95% CI, 0.75-0.97; P=0.02). We found that a decrease in the incidences of death due to GVHD and infection contributed to the reduction in NRM, to which high-resolution donor-recipient HLA matching and other improvements may have contributed. As none of the subgroups showed improved survival without a reduction in NRM, the effective prevention of transplant-related complications appears to be necessary for improving outcomes after allo-HCT in non-remission.
机译:尽管已经表明异基因造血细胞移植(allo-HCT)后的结局有近期改善,但基于患者年龄,供体来源,关于在非缓解的异源HCT后移植方式变化如何影响结局的信息很少,和疾病类型。我们使用全国移植结果登记数据库,比较了连续三年的三年中非缓解性异种-HCT发生后非复发死亡率(NRM)的发生率和原因。共分析了3308例未缓解的急性白血病患者。在这三个阶段中,NRM的风险均降低了,与1997-2000年相比,2001-2004年和2005-2008年的危险比(HRs)为0.86(95%CI,0.70-1.06; P = 0.16)和0.65(95%) CI,0.53-0.80; P <0.01)。在2005-2008年,HR的总体死亡率也显着下降(HR 0.85; 95%CI,0.75-0.97; P = 0.02)。我们发现,由于GVHD和感染而导致死亡的减少导致NRM的减少,而高分辨率的供体-受体HLA匹配和其他改善可能有助于NRM的减少。由于这些亚组均未显示生存率提高而NRM却没有降低,因此有效预防移植相关并发症似乎是改善非缓解异体HCT后预后的必要条件。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号